Serologic discrimination of human T cell lymphotropic virus infection by using a synthetic peptide-based enzyme immunoassay. 1991

R B Lal, and D L Rudolph, and M D Lairmore, and R F Khabbaz, and M Garfield, and J E Coligan, and T M Folks
Retrovirus Diseases Branch, Centers for Disease Control, Atlanta, Georgia 30333.

Synthetic peptides corresponding with unique regions of the envelope glycoproteins (gp46) of human T cell lymphotropic viruses (HTLVs) were used in an enzyme immunoassay to determine if HTLV-I and -II infections could be discriminated. Two synthetic HTLV-I sequence-derived peptides, Env-1 (amino acids 191-215) and Env-5 (amino acids 242-257), reacted with 92% and 100% of the serum specimens (n = 52) from HTLV-I-infected persons, respectively. Although a small percentage (8.6%) of serum specimens from persons infected with HTLV-II cross-reacted with Env-1, none of these specimens reacted with Env-5. Peptide Env-2 encoded by the envelope region of HTLV-II (amino acids 187-210) reacted with serum specimens from both HTLV-I (94%)- and HTLV-II (74%)-infected patients, whereas Env-6, another HTLV-II peptide (amino acids 238-254), reacted with less than 6% of the specimens. Therefore, the Env-5 peptide with amino acid sequence SerProAsnValSerValProSerSerSerSerThrProLeuLeuTyr represents an immunodominant domain of HTLV-I that is recognized by serum antibodies from all HTLV-I-infected persons. Moreover, the Env-5-based ELISA allows a categorical distinction between the closely related HTLV-I and -II infections.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D015481 HTLV-I Antibodies Antibodies reactive with the HTLV-I ANTIGENS. ATLV Antibodies,Human T-Cell Leukemia Virus I Antibodies,Leukemia-Lymphoma Virus I Antibodies, Human T-Cell,T-Cell Leukemia Virus I Antibodies, Adult,T-Cell Leukemia Virus I Antibodies, Human,HTLV I Antibodies,Human T Cell Leukemia Virus I Antibodies,Leukemia Lymphoma Virus I Antibodies, Human T Cell,T Cell Leukemia Virus I Antibodies, Adult,T Cell Leukemia Virus I Antibodies, Human,Antibodies, ATLV,Antibodies, HTLV I,Antibodies, HTLV-I,I Antibodies, HTLV

Related Publications

R B Lal, and D L Rudolph, and M D Lairmore, and R F Khabbaz, and M Garfield, and J E Coligan, and T M Folks
April 1992, Journal of medical virology,
R B Lal, and D L Rudolph, and M D Lairmore, and R F Khabbaz, and M Garfield, and J E Coligan, and T M Folks
April 1992, Journal of clinical microbiology,
R B Lal, and D L Rudolph, and M D Lairmore, and R F Khabbaz, and M Garfield, and J E Coligan, and T M Folks
November 1986, The Journal of clinical investigation,
R B Lal, and D L Rudolph, and M D Lairmore, and R F Khabbaz, and M Garfield, and J E Coligan, and T M Folks
January 1998, Clinical and diagnostic laboratory immunology,
R B Lal, and D L Rudolph, and M D Lairmore, and R F Khabbaz, and M Garfield, and J E Coligan, and T M Folks
March 1987, Ugeskrift for laeger,
R B Lal, and D L Rudolph, and M D Lairmore, and R F Khabbaz, and M Garfield, and J E Coligan, and T M Folks
October 2000, Neurologia (Barcelona, Spain),
R B Lal, and D L Rudolph, and M D Lairmore, and R F Khabbaz, and M Garfield, and J E Coligan, and T M Folks
January 1992, Journal of clinical laboratory analysis,
R B Lal, and D L Rudolph, and M D Lairmore, and R F Khabbaz, and M Garfield, and J E Coligan, and T M Folks
May 1996, The Australasian journal of dermatology,
R B Lal, and D L Rudolph, and M D Lairmore, and R F Khabbaz, and M Garfield, and J E Coligan, and T M Folks
May 1990, International journal of cancer,
R B Lal, and D L Rudolph, and M D Lairmore, and R F Khabbaz, and M Garfield, and J E Coligan, and T M Folks
May 1990, Journal of clinical microbiology,
Copied contents to your clipboard!